The effects of an orally administered cholinergic agonist on REM sleep in major depression

Michael L. Perlis, Michael T Smith, Henry J. Orff, Patrick J. Andrews, J. Christian Gillin, Donna E. Giles

Research output: Contribution to journalArticle

Abstract

Background: Centrally active cholinergic agents such as arecoline and physostigmine shorten rapid eye movement (REM) latency, reduce REM interval times, or both and do so preferentially in patients with depression. We tested an orally administered cholinergic agonist (donepezil HCL 10 mg [Aricept]) to determine whether this agent also alters REM timing in depressed patients (n = 8) compared with age- and gender-matched control subjects (n = 8). Methods: All subjects were studied for 3 consecutive nights in the sleep laboratory. The design was a fixed-order placebo-donepezil protocol to accommodate the long half-life of donepezil. Night 1 served as an adaptation night. On night 2, placebo was administered at 8:00 PM. On night 3, donepezil was administered at 8:00 PM. Results: The cholinergic challenge distinguished the groups. In depressed patients REM latency was reduced compared with baseline (47.6 vs. 64.4, p = .04) following administration of donepezil. Control subjects showed no response: REM latency after donepezil was virtually identical to baseline REM latency (71.7 vs. 69.3). Conclusions: These data indicate that donepezil is likely to be useful in testing hypotheses related to cholinergic function in mood disorders.

Original languageEnglish (US)
Pages (from-to)457-462
Number of pages6
JournalBiological Psychiatry
Volume51
Issue number6
DOIs
StatePublished - Mar 15 2002
Externally publishedYes

Fingerprint

Cholinergic Agonists
REM Sleep
Sleep
Depression
Cholinergic Agents
Placebos
Arecoline
Physostigmine
donepezil
Mood Disorders
Half-Life

Keywords

  • Aricept
  • Cholinergic agonist
  • Depression
  • Donepezil
  • REM sleep

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

The effects of an orally administered cholinergic agonist on REM sleep in major depression. / Perlis, Michael L.; Smith, Michael T; Orff, Henry J.; Andrews, Patrick J.; Gillin, J. Christian; Giles, Donna E.

In: Biological Psychiatry, Vol. 51, No. 6, 15.03.2002, p. 457-462.

Research output: Contribution to journalArticle

Perlis, Michael L. ; Smith, Michael T ; Orff, Henry J. ; Andrews, Patrick J. ; Gillin, J. Christian ; Giles, Donna E. / The effects of an orally administered cholinergic agonist on REM sleep in major depression. In: Biological Psychiatry. 2002 ; Vol. 51, No. 6. pp. 457-462.
@article{e447cb37a8a04a889f7bc5ce32c743cb,
title = "The effects of an orally administered cholinergic agonist on REM sleep in major depression",
abstract = "Background: Centrally active cholinergic agents such as arecoline and physostigmine shorten rapid eye movement (REM) latency, reduce REM interval times, or both and do so preferentially in patients with depression. We tested an orally administered cholinergic agonist (donepezil HCL 10 mg [Aricept]) to determine whether this agent also alters REM timing in depressed patients (n = 8) compared with age- and gender-matched control subjects (n = 8). Methods: All subjects were studied for 3 consecutive nights in the sleep laboratory. The design was a fixed-order placebo-donepezil protocol to accommodate the long half-life of donepezil. Night 1 served as an adaptation night. On night 2, placebo was administered at 8:00 PM. On night 3, donepezil was administered at 8:00 PM. Results: The cholinergic challenge distinguished the groups. In depressed patients REM latency was reduced compared with baseline (47.6 vs. 64.4, p = .04) following administration of donepezil. Control subjects showed no response: REM latency after donepezil was virtually identical to baseline REM latency (71.7 vs. 69.3). Conclusions: These data indicate that donepezil is likely to be useful in testing hypotheses related to cholinergic function in mood disorders.",
keywords = "Aricept, Cholinergic agonist, Depression, Donepezil, REM sleep",
author = "Perlis, {Michael L.} and Smith, {Michael T} and Orff, {Henry J.} and Andrews, {Patrick J.} and Gillin, {J. Christian} and Giles, {Donna E.}",
year = "2002",
month = "3",
day = "15",
doi = "10.1016/S0006-3223(01)01287-2",
language = "English (US)",
volume = "51",
pages = "457--462",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - The effects of an orally administered cholinergic agonist on REM sleep in major depression

AU - Perlis, Michael L.

AU - Smith, Michael T

AU - Orff, Henry J.

AU - Andrews, Patrick J.

AU - Gillin, J. Christian

AU - Giles, Donna E.

PY - 2002/3/15

Y1 - 2002/3/15

N2 - Background: Centrally active cholinergic agents such as arecoline and physostigmine shorten rapid eye movement (REM) latency, reduce REM interval times, or both and do so preferentially in patients with depression. We tested an orally administered cholinergic agonist (donepezil HCL 10 mg [Aricept]) to determine whether this agent also alters REM timing in depressed patients (n = 8) compared with age- and gender-matched control subjects (n = 8). Methods: All subjects were studied for 3 consecutive nights in the sleep laboratory. The design was a fixed-order placebo-donepezil protocol to accommodate the long half-life of donepezil. Night 1 served as an adaptation night. On night 2, placebo was administered at 8:00 PM. On night 3, donepezil was administered at 8:00 PM. Results: The cholinergic challenge distinguished the groups. In depressed patients REM latency was reduced compared with baseline (47.6 vs. 64.4, p = .04) following administration of donepezil. Control subjects showed no response: REM latency after donepezil was virtually identical to baseline REM latency (71.7 vs. 69.3). Conclusions: These data indicate that donepezil is likely to be useful in testing hypotheses related to cholinergic function in mood disorders.

AB - Background: Centrally active cholinergic agents such as arecoline and physostigmine shorten rapid eye movement (REM) latency, reduce REM interval times, or both and do so preferentially in patients with depression. We tested an orally administered cholinergic agonist (donepezil HCL 10 mg [Aricept]) to determine whether this agent also alters REM timing in depressed patients (n = 8) compared with age- and gender-matched control subjects (n = 8). Methods: All subjects were studied for 3 consecutive nights in the sleep laboratory. The design was a fixed-order placebo-donepezil protocol to accommodate the long half-life of donepezil. Night 1 served as an adaptation night. On night 2, placebo was administered at 8:00 PM. On night 3, donepezil was administered at 8:00 PM. Results: The cholinergic challenge distinguished the groups. In depressed patients REM latency was reduced compared with baseline (47.6 vs. 64.4, p = .04) following administration of donepezil. Control subjects showed no response: REM latency after donepezil was virtually identical to baseline REM latency (71.7 vs. 69.3). Conclusions: These data indicate that donepezil is likely to be useful in testing hypotheses related to cholinergic function in mood disorders.

KW - Aricept

KW - Cholinergic agonist

KW - Depression

KW - Donepezil

KW - REM sleep

UR - http://www.scopus.com/inward/record.url?scp=0037087349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037087349&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(01)01287-2

DO - 10.1016/S0006-3223(01)01287-2

M3 - Article

C2 - 11922879

AN - SCOPUS:0037087349

VL - 51

SP - 457

EP - 462

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 6

ER -